Maxim Sysoev

Maxim Sysoev

Auto-generated profile, based on publicly available information

Maxim Sysoev

Granov Russian Research Centre of Radiology and Surgical Technologies, Ministry of Healthcare of Russian Federation, St. Petersburg, Russia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Brain Research Bulletin
Verified
Journal Article
Closed access
MAMurilo Sander de Abreu
Murilo Sander de Abreu
AGAna C.V.V. Giacomini
Ana C.V.V. Giacomini
MSMaksim Sysoev
Maksim Sysoev
KDKonstantin Demin
Konstantin Demin
PAPolina A. Alekseeva
Polina A. Alekseeva
AKAllan V. Kalueff
Allan V. Kalueff

1 May 2019 in Aquatic Toxicology
Verified
Journal Article
Closed access
KDKonstantin Demin
Konstantin Demin
ALAnton M. Lakstygal
Anton M. Lakstygal
PAPolina A. Alekseeva
Polina A. Alekseeva
MSMaxim Sysoev
Maxim Sysoev
MAMurilo Sander de Abreu
Murilo Sander de Abreu
AKAllan V. Kalueff
Allan V. Kalueff

22 February 2019 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
KDKonstantin A. Demin
Konstantin A. Demin
MSMaxim Sysoev
Maxim Sysoev
MCMaria V. Chernysh
Maria V. Chernysh
ASAnna K. Savva
Anna K. Savva
MKMamiko Koshiba
Mamiko Koshiba
AKAllan V. Kalueff
Allan V. Kalueff
Introduction: Depression is a highly debilitating psychiatric disorder that affects the global population and causes severe disabilities and suicide. Depression pathogenesis remains poorly understood, and the disorder is often treatment-resistant and recurrent, necessitating the development of novel therapies, models and concepts in this field. Areas covered: Animal models are indispensable for translational biological psychiatry, and markedly advance the study of depression. Novel approaches continuously emerge that may help untangle the disorder heterogeneity and unclear categories of disease classification systems. Some of these approaches include widening the spectrum of model species used for translational research, using a broader range of test paradigms, exploring new pathogenic pathways and biomarkers, and focusing more closely on processes beyond neural cells (e.g. glial, inflammatory and metabolic deficits). Expert opinion: Dividing the core symptoms into easily translatable, evolutionarily conserved phenotypes is an effective way to reevaluate current depression modeling. Conceptually novel approaches based on the endophenotype paradigm, cross-species trait genetics and ‘domain interplay concept’, as well as using a wider spectrum of model organisms and target systems will enhance experimental modeling of depression and antidepressant drug discovery.